RWE Aktiengesellschaft (RWE.F)
| Previous close | 33.31 |
| Open | 33.47 |
| Bid | 33.39 x 382800 |
| Ask | 33.46 x 382500 |
| Day's range | 33.22 - 33.53 |
| 52-week range | 30.10 - 42.80 |
| Volume | |
| Avg. volume | 8,841 |
| Market cap | 24.8B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | 17.10 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.00 (3.00%) |
| Ex-dividend date | 06 May 2024 |
| 1y target est | N/A |
- Globe Newswire
World Healthcare Data Research Report 2023: RWD/RWE Enabling New Models of Research and Care Delivery
RWD Market Forecast RWD Market Forecast Data cleaning process for RWD via Duke Margolis Center Data cleaning process for RWD via Duke Margolis Center Breadth of different capabilities and tools that are utilized or enabled by RWD Breadth of different capabilities and tools that are utilized or enabled by RWD Dublin, Nov. 10, 2023 (GLOBE NEWSWIRE) -- The "Getting Real with Healthcare Data: RWD/RWE Enabling New Models of Research and Care Delivery" report has been added to ResearchAndMarkets.com's
- Globe Newswire
European Real-World Evidence and Data Analytics Conference 2023: Revolutionizing Healthcare with RWD / RWE to Accelerate Regulatory Decision Making (Frankfurt, Germany - October 5-6, 2023)
Dublin, Aug. 18, 2023 (GLOBE NEWSWIRE) -- The "Real-World Evidence and Data Analytics Conference" conference has been added to ResearchAndMarkets.com's offering.Revolutionizing Healthcare with RWD / RWE to Accelerate Regulatory Decision Making Real-world data and real-world evidence are poised to keep making strides in 2023. This analysis of clinical evidence studies the usage, potential advantages, and risk of a medical product inferred from real-world data analysis. Real-world evidence (RWE) i
